ClinicalTrials.gg
CompletedNCT02750592Updated Sep 9, 2019Results posted

Study of Efficacy and Safety of Secukinumab in Japanese Patients With Active Ankylosing Spondylitis

A Phase 3 interventional study of Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection. in Ankylosing Spondylitis, sponsored by Novartis Pharmaceuticals. Completed at 10 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-09.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing secukinumab in Spondylitis, Ankylosing — 3 open to participants now, 4 under way, none of them phase 3. secukinumab · Spondylitis, Ankylosing.

Enrollment
19th of 20
30 · median 223
Started
2016
with 3 others
Phase 3
11 of 20
none open now
Registered
9th of 20
by date
Lead sponsor
15 of 20
Novartis Pharmaceuticals

Among the 20 studies testing secukinumab in Spondylitis, Ankylosing, this one is the 19th largest by enrollment, is one of 4 that started in 2016, is one of 11 in phase 3, and was the 9th registered.

Spondylitis, Ankylosing

533 studies on the registry are indexed under Spondylitis, Ankylosing; 99 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

3 of the 20 studies testing secukinumab in Spondylitis, Ankylosing are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 25 (40%) set no upper age limit and 32 (51%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing secukinumab in Spondylitis, Ankylosing, or all of them as a file.
02

Study summary

The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.

03

Conditions studied

  • Ankylosing Spondylitis

Keywords

  • Ankylosing Spondylitis
  • secukinumab
  • AIN457H
  • SpondyloArthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS with active AS assessed by BASDAI ≥ 4 (0-10) and spinal pain as measured by VAS≥ 4 cm (BASDAI question #2) at Baseline
  • Patients should have been on NSAIDs at the highest recommended dose for at least 3 months prior to baseline with an inadequate response or failure to respond, or less than 3 months if therapy had to be withdrawn due to intolerance, toxicity or
  • Patients who have been on a TNFα inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or have been intolerant to at least one administration of an anti-TNFα agent

Exclusion criteria

Exclusion Criteria:

  • Patients with total ankylosis of the spine
  • Patients previously treated with any biological immunomodulating agents except for those targeting TNFα
  • Active ongoing inflammatory diseases other than AS that might confound the evaluation of the benefit of secukinumab therapy, including inflammatory bowel disease or uveitis
  • Known infection with , or at screening or baseline
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    secukinumab 150mg

    A screening (SCR) epoch running 4-10 weeks before baseline (BSL) was used to assess eligibility followed by 52 weeks of treatment. The treatment periods consist of Treatment period 1 (BSL to Week 24) and Treatment period 2 (Week 24 to Week 52). After Week 52 follows a post-treatment follow-up until Week 60. A follow-up visit was done at 12 weeks after last study treatment administration for all patients, regardless of whether they completed the entire study as planned (Week 60) or discontinue prematurely.

    Drug: Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.

Interventions

06

What researchers measure

Primary outcomes

  1. Assessment of SpondyloArthritis International Society 20 Response (ASAS20)

    This table is ASAS20 response using non-responder imputation for FAS It assesses the efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline in Japanese patients with active AS based on the proportion of patients achieving an ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response. The ASAS Response Criteria (ASAS 20) is defined as an improvement of ≥ 20% and ≥ 1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥ 20% and ≥ 1 unit on a scale of 10 in the remaining domain

    Time frame: week 16

Secondary outcomes

  1. ASAS 40 Response Rate With Non-responder Imputation (NRI)

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS 40 response ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain

    Time frame: Week 16

  2. Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 response The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline

    Time frame: Week 16

  3. Change in High Sensitivity C-Reactive Protein (hsCRP)

    hsCRP (mg/L) change from baseline using observed data with log e transformation The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP) hsCRP is measured as a marker of inflammation from blood samples during the study

    Time frame: baseline, Week 16

  4. Number of Participants With ASAS 5/6 Response Criteria

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients meeting the ASAS 5/6 response criteria The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains

    Time frame: Week 16

  5. Mean Change From Baseline in BASDAI From Baseline

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in total BASDAI The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS Each question (question 1 to 6) is scored from 0 to 10 (0 being no problem and 10 being the worst problem). To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.

    Time frame: Baseline, week 16

  6. Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score

    SF-36 PCS, mean change from baseline: The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions Score range is from 0 (no problems) to 100 (unable to perform the activity) SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline. There is no total overall score; scoring is computed for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.

    Time frame: Baseline, week 16

  7. Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity)

    Time frame: Baseline, week 16

  8. Proportion of Participants Achieving ASAS Partial Remission

    The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS partial remission The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10

    Time frame: week 16

  9. Change in Serum Concentration of Secukinumab

    The assessment of pre dose concentration of secukinumab in Japanese AS patients An enzyme-linked immunosorbent assay (ELISA) method will be used for bioanalytical analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL.

    Time frame: Baseline, weeks 4, 16, 24, 52, 60

  10. Number of Participants With Immunogenicity Against Secukinumab

    Concentration of anti-secukinumab antibodies Assessment of immunogenicity against secukinumab by concentration of anti-secukinumab antibodies at pre-dose. An electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.

    Time frame: week 60

  11. Number of Participants With Newly Occurring or Worsening Hematology Abnormalities Based on CTCAE Grade, Blood

    Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

    Time frame: week 60

  12. Number of Participants With Newly Occurring or Worsening Chemistry Abnormalities Based on CTCAE Grade

    Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL include preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL include bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

    Time frame: week 60

  13. Participants With Newly Occurring or Worsening Liver Enzyme Abnormalities

    During the entire safety reporting period, mean values of each liver enzyme parameter stayed within the normal range and were comparable to the baseline values ALP=Alkaline phosphatase ALT=Alanine aminotransferase AST=Aspartate aminotransferase TBL=Total bilirubin ULN=Upper Limit Normal

    Time frame: week 60

  14. Number of Participants With Newly Occurring or Worsening Lipid Parameters Abnormalities

    During the entire safety reporting period, mean values of each lipid parameter stayed within the normal range and were comparable to the baseline values

    Time frame: week 60

  15. Participants With Newly Occurring Notable Abnormalities in Vital Signs

    Sitting Pulse (bpm) High only (\> 100 bpm) Low only (\< 60 bpm) Low and High (\< 60 bpm and \> 100 bpm) Sitting Diastolic Blood Pressure (BP) (mmHg) High only (≥ 90 mmHg) Low only (\< 60 mmHg) Low and High (\< 60 mmHg and ≥ 90 mmHg) Sitting Systolic Blood Pressure (mmHg) High only (≥ 140 mmHg) Low only (\< 90 mmHg) Low and High (\< 90 mmHg and ≥ 140 mmHg)

    Time frame: week 60

07

Results

Posted Sep 9, 2019
Limitations and caveats
This single arm study has no comparator and therefore no statistical test for comparison was planned for the outcome measures

Participant flow

A total of 37 patients were screened, and 30 patients (81.1%) completed the screening phase and entered Treatment Period

Participant flow — Overall Study
MilestoneSecukinumab 150mg
Started30
Completed25
Not completed5
Withdrew: Adverse event3
Withdrew: Lack of efficacy2

Outcome measures

PrimaryAssessment of SpondyloArthritis International Society 20 Response (ASAS20)

This table is ASAS20 response using non-responder imputation for FAS It assesses the efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline in Japanese patients with active AS based on the proportion of patients achieving an ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response. The ASAS Response Criteria (ASAS 20) is defined as an improvement of ≥ 20% and ≥ 1 unit on a scale of 10 in at least three of the four main domains and no worsening of ≥ 20% and ≥ 1 unit on a scale of 10 in the remaining domain

Time frame:
week 16
Reported as:
Number · participants
Assessment of SpondyloArthritis International Society 20 Response (ASAS20)
participantsSecukinumab 150mg
Assessment of SpondyloArthritis International Society 20 Response (ASAS20)21
SecondaryASAS 40 Response Rate With Non-responder Imputation (NRI)

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS 40 response ASAS40 response is defined as an improvement of ≥40% and ≥2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain

Time frame:
Week 16
Reported as:
Number · participants
ASAS 40 Response Rate With Non-responder Imputation (NRI)
participantsSecukinumab 150mg
ASAS 40 Response Rate With Non-responder Imputation (NRI)14
SecondaryBath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 response The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline

Time frame:
Week 16
Reported as:
Number · participants
Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate
participantsSecukinumab 150mg
Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate11
SecondaryChange in High Sensitivity C-Reactive Protein (hsCRP)

hsCRP (mg/L) change from baseline using observed data with log e transformation The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP) hsCRP is measured as a marker of inflammation from blood samples during the study

Time frame:
baseline, Week 16
Reported as:
Geometric mean · mg/L
Change in High Sensitivity C-Reactive Protein (hsCRP)
mg/LSecukinumab 150mg
Change in High Sensitivity C-Reactive Protein (hsCRP)0.247 (0.125 to 0.487)
SecondaryNumber of Participants With ASAS 5/6 Response Criteria

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients meeting the ASAS 5/6 response criteria The ASAS 5/6 improvement criteria is an improvement of ≥20% in at least five of all six domains

Time frame:
Week 16
Reported as:
Number · participants
Number of Participants With ASAS 5/6 Response Criteria
participantsSecukinumab 150mg
Number of Participants With ASAS 5/6 Response Criteria14
SecondaryMean Change From Baseline in BASDAI From Baseline

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in total BASDAI The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS Each question (question 1 to 6) is scored from 0 to 10 (0 being no problem and 10 being the worst problem). To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.

Time frame:
Baseline, week 16
Reported as:
Mean · scores on a scale
Mean Change From Baseline in BASDAI From Baseline
scores on a scaleSecukinumab 150mg
Mean Change From Baseline in BASDAI From Baseline-3.088 ± 2.0697
SecondaryChange From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score

SF-36 PCS, mean change from baseline: The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions Score range is from 0 (no problems) to 100 (unable to perform the activity) SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline. There is no total overall score; scoring is computed for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.

Time frame:
Baseline, week 16
Reported as:
Mean · scores on a scale
Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score
scores on a scaleSecukinumab 150mg
Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score6.306 ± 8.0724
SecondaryChange From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL) The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity)

Time frame:
Baseline, week 16
Reported as:
Mean · scores on a scale
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score
scores on a scaleSecukinumab 150mg
Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score-3.40 ± 4.00
SecondaryProportion of Participants Achieving ASAS Partial Remission

The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS partial remission The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10

Time frame:
week 16
Reported as:
Number · participants
Proportion of Participants Achieving ASAS Partial Remission
participantsSecukinumab 150mg
Proportion of Participants Achieving ASAS Partial Remission6 ± 20.0
SecondaryChange in Serum Concentration of Secukinumab

The assessment of pre dose concentration of secukinumab in Japanese AS patients An enzyme-linked immunosorbent assay (ELISA) method will be used for bioanalytical analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL.

Time frame:
Baseline, weeks 4, 16, 24, 52, 60
Reported as:
Mean · μg/mL
Change in Serum Concentration of Secukinumab
μg/mLSecukinumab 150mg
week 451.3 ± 15.35
week 1625.0 ± 10.19
week 2422.2 ± 8.96
week 5221.1 ± 6.08
week 606.2 ± 3.61
SecondaryNumber of Participants With Immunogenicity Against Secukinumab

Concentration of anti-secukinumab antibodies Assessment of immunogenicity against secukinumab by concentration of anti-secukinumab antibodies at pre-dose. An electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.

Time frame:
week 60
Reported as:
Number · participants
Number of Participants With Immunogenicity Against Secukinumab
participantsSecukinumab 150mg
Number of Participants With Immunogenicity Against Secukinumab0
SecondaryNumber of Participants With Newly Occurring or Worsening Hematology Abnormalities Based on CTCAE Grade, Blood

Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

Time frame:
week 60
Reported as:
Number · participants
Number of Participants With Newly Occurring or Worsening Hematology Abnormalities Based on CTCAE Grade, Blood
participantsSecukinumab 150mg
Hemoglobin (g/L) <LLN - 100 g/L (Grade1)6
Hemoglobin (g/L) <100 - 80 g/L (Grade2)0
Hemoglobin (g/L) < 80g/L (Grade3)0
Lymphocytes (10E9/L) <LLN - 0.8 × 10e9/L (Grade1)2
Lymphocytes (10E9/L) <0.8 - 0.5 × 10e9/L (Grade2)1
Lymphocytes (10E9/L) <0.5 - 0.2 × 10e9/L (Grade3)1
Lymphocytes (10E9/L) <0.2 × 10e9/L (Grade4)0
Neutrophils (10E9/L) < LLN - 1.5 × 10e9/L (Grade1)0
Neutrophils (10E9/L) < 1.5 - 1.0 × 10e9/L (Grade2)1
Neutrophils (10E9/L) < 1.0 - 0.5 × 10e9/L (Grade3)0
Neutrophils (10E9/L) < 0.5 × 10e9/L (Grade4)0
Platelets (10E9/L) <LLN - 75.0 ×10e9/L (Grade1)3
Platelets (10E9/L) <75.0 - 50.0 ×10e9/L (Grade2)0
Platelets (10E9/L) <50.0 - 25.0 ×10e9/L (Grade3)0
Platelets (10E9/L), Blood <25.0 ×10e9/L (Grade4)0
Leukocytes (10E9/L) <LLN - 3.0 × 10e9/L (Grade1)0
Leukocytes (10E9/L) <3.0 - 2.0 × 10e9/L (Grade2)1
Leukocytes (10E9/L) <2.0 - 1.0 × 10e9/L (Grade3)0
Leukocytes (10E9/L) <1.0 × 10e9/L (Grade4)0
SecondaryNumber of Participants With Newly Occurring or Worsening Chemistry Abnormalities Based on CTCAE Grade

Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)\*. Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL\*\*. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE. \*Instrumental ADL include preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. \*\*Self care ADL include bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.

Time frame:
week 60
Reported as:
Number · participants
Number of Participants With Newly Occurring or Worsening Chemistry Abnormalities Based on CTCAE Grade
participantsSecukinumab 150mg
Alkaline Phosphatase (U/L), Serum (Grade1)3
Alkaline Phosphatase (U/L), Serum (Grade2)0
Alkaline Phosphatase (U/L), Serum (Grade3)0
Alkaline Phosphatase (U/L), Serum (Grade4)0
Alanine Aminotransferase (U/L), Serum (Grade1)3
Alanine Aminotransferase (U/L), Serum (Grade2)0
Alanine Aminotransferase (U/L), Serum (Grade3)0
Alanine Aminotransferase (U/L), Serum (Grade4)0
Aspartate Aminotransferase (U/L), Serum (Grade1)4
Aspartate Aminotransferase (U/L), Serum (Grade2)0
Aspartate Aminotransferase (U/L), Serum (Grade3)0
Aspartate Aminotransferase (U/L), Serum (Grade4)0
Bilirubin (umol/L), Serum (Grade1)2
Bilirubin (umol/L), Serum (Grade2)1
Bilirubin (umol/L), Serum (Grade3)0
Bilirubin (umol/L), Serum (Grade4)0
Cholesterol (mmol/L), Serum (Grade1) Serum4
Cholesterol (mmol/L), Serum (Grade2)0
Cholesterol (mmol/L), Serum (Grade3)0
Cholesterol (mmol/L), Serum (Grade4)0
Creatinine (umol/L), Plasma/Serum (Grade1)1
Creatinine (umol/L), Plasma/Serum (Grade2)0
Creatinine (umol/L), Plasma/Serum (Grade3)0
Creatinine (umol/L), Plasma/Serum (Grade4) Serum0
Gamma Glutamyl Transferase (U/L), Serum (Grade1)1
Gamma Glutamyl Transferase (U/L), Serum (Grade2)0
Gamma Glutamyl Transferase (U/L), Serum (Grade3)0
Gamma Glutamyl Transferase (U/L), Serum (Grade4)0
Glucose Decreased (mmol/L), Plasma (Grade1)0
Glucose Decreased (mmol/L), Plasma (Grade2)0
Glucose Decreased (mmol/L), Plasma (Grade3)0
Glucose Decreased (mmol/L), Plasma (Grade4)0
Glucose Increased (mmol/L), Plasma (Grade1)12
Glucose Increased (mmol/L), Plasma (Grade2)3
Glucose Increased (mmol/L), Plasma (Grade3)1
Glucose Increased (mmol/L), Plasma (Grade4)0
Triglycerides (mmol/L), Plasma/Serum (Grade1)9
Triglycerides (mmol/L), Plasma/Serum (Grade2)1
Triglycerides (mmol/L), Plasma/Serum (Grade3)0
Triglycerides (mmol/L), Plasma/Serum (Grade4)0
SecondaryParticipants With Newly Occurring or Worsening Liver Enzyme Abnormalities

During the entire safety reporting period, mean values of each liver enzyme parameter stayed within the normal range and were comparable to the baseline values ALP=Alkaline phosphatase ALT=Alanine aminotransferase AST=Aspartate aminotransferase TBL=Total bilirubin ULN=Upper Limit Normal

Time frame:
week 60
Reported as:
Number · participants
Participants With Newly Occurring or Worsening Liver Enzyme Abnormalities
participantsSecukinumab 150mg
ALT > 3 × ULN0
ALT > 5 × ULN0
ALT > 8 × ULN0
ALT > 10 × ULN0
ALT > 20 × ULN0
AST > 3 × ULN0
AST > 5 × ULN0
AST > 8 × ULN0
AST > 10 × ULN0
AST > 20 × ULN0
ALT or AST > 3 × ULN0
ALT or AST > 5 × ULN0
ALT or AST > 8 × ULN0
ALT or AST > 10 × ULN0
ALT or AST > 20 × ULN0
TBL > 1.5 × ULN1
TBL > 2 × ULN0
TBL > 3 × ULN0
ALP > 2 × ULN0
ALP > 3 × ULN0
ALP > 5 × ULN0
ALT or AST > 3 × ULN & TBL > 2 × ULN0
ALT or AST > 5 × ULN & TBL > 2 × ULN0
ALT or AST > 8 × ULN & TBL > 2 × ULN0
ALT or AST > 10 × ULN & TBL > 2 × ULN0
ALP > 3 × ULN & TBL > 2 × ULN0
ALP > 5 × ULN & TBL > 2 × ULN0
ALT or AST> 3 × ULN & TBL> 2 × ULN & ALP <2 × ULN0
SecondaryNumber of Participants With Newly Occurring or Worsening Lipid Parameters Abnormalities

During the entire safety reporting period, mean values of each lipid parameter stayed within the normal range and were comparable to the baseline values

Time frame:
week 60
Reported as:
Number · participants
Number of Participants With Newly Occurring or Worsening Lipid Parameters Abnormalities
participantsSecukinumab 150mg
HDL: ≤ LLN5
HDL: < 0.8 × LLN1
LDL: ≥ ULN1
LDL: > 1.5 × ULN0
LDL: > 2.5 × ULN0
Cholesterol: ≥ ULN4
Cholesterol: > 1.5 × ULN0
Cholesterol: > 2.5 × ULN0
Triglycerides: ≥ ULN8
Triglycerides: > 1.5 × ULN4
Triglycerides: > 2.5 × ULN0
SecondaryParticipants With Newly Occurring Notable Abnormalities in Vital Signs

Sitting Pulse (bpm) High only (\> 100 bpm) Low only (\< 60 bpm) Low and High (\< 60 bpm and \> 100 bpm) Sitting Diastolic Blood Pressure (BP) (mmHg) High only (≥ 90 mmHg) Low only (\< 60 mmHg) Low and High (\< 60 mmHg and ≥ 90 mmHg) Sitting Systolic Blood Pressure (mmHg) High only (≥ 140 mmHg) Low only (\< 90 mmHg) Low and High (\< 90 mmHg and ≥ 140 mmHg)

Time frame:
week 60
Reported as:
Number · participants
Participants With Newly Occurring Notable Abnormalities in Vital Signs
participantsSecukinumab 150mg
Sitting Pulse (bpm) High only2
Sitting Pulse (bpm) Low only5
Sitting Pulse (bpm) Low and High0
Sitting Diastolic BP (mmHg), High only8
Sitting Diastolic BP (mmHg), Low only5
Sitting Diastolic BP (mmHg), Low and high0
Sitting Systolic BP (mmHg) High only12
Sitting Systolic BP (mmHg) Low only0
Sitting Systolic BP (mmHg) Low and High0

Adverse events

Collected over AEs and SAEs were collected for the maximum duration of treatment and follow up for a participant per protocol for approximately 60 weeks. All cause mortality (deaths) was collected from First Patient First Visit (FPFV) to Last Patient Last Visit (LPLV) up to a maximum of 60 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AIN457 150mg0/30 (0%)3/30 (10%)26/30 (86.7%)
Most frequent serious events
Most frequent serious events
EventAIN457 150mg
Coronary artery occlusionCardiac disorders1/30
Adenocarcinoma of the cervixNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30
Drug eruptionSkin and subcutaneous tissue disorders1/30
Most frequent other events
Showing 10 of 13
Most frequent other events
EventAIN457 150mg
NasopharyngitisInfections and infestations15/30
StomatitisGastrointestinal disorders7/30
InfluenzaInfections and infestations5/30
GastroenteritisInfections and infestations3/30
LeukopeniaBlood and lymphatic system disorders2/30
DiarrhoeaGastrointestinal disorders2/30
PyrexiaGeneral disorders2/30
BronchitisInfections and infestations2/30
Infected dermal cystInfections and infestations2/30
PharyngitisInfections and infestations2/30

Baseline characteristics

The safety set included all patients who took at least one dose of study treatment during the treatment periods.

Age, Continuous
Age, Continuous(years)Secukinumab 150mg
Mean44.0 ± 13.25
Age, Customized
Age, Customized(Participants)Secukinumab 150mg
<65 years27
>=65years3
>=75 years0
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 150mg
Female10
Male20
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Secukinumab 150mg
Asian30
Other0
08

Study locations

10 sites
  • Novartis Investigative Site
    Kitakyushu-city, Fukuoka 807-8556, Japan
  • Novartis Investigative Site
    Kita-gun, Kagawa 761-0793, Japan
  • Novartis Investigative Site
    Nankoku city, Kochi 783 8505, Japan
  • Novartis Investigative Site
    Tenri, Nara 632-8552, Japan
  • Novartis Investigative Site
    Okayama-city, Okayama 700-0013, Japan
  • Novartis Investigative Site
    Kawachinagano, Osaka 586-8521, Japan
  • Novartis Investigative Site
    Suita city, Osaka 565 0871, Japan
  • Novartis Investigative Site
    Bunkyo ku, Tokyo 113-8431, Japan
  • Novartis Investigative Site
    Chuo ku, Tokyo 104-8560, Japan
  • Novartis Investigative Site
    Shinjuku-ku, Tokyo 160-0054, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2016 to primary completion in Jul 2017, 15 months.

Results were first posted in Sep 2019, 2 years 2 months after primary completion.

Of 38 industry-sponsored phase 3 interventional studies under Spondylitis, Ankylosing, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 28. This study's 15 months is below that.

Counting every sponsor, half of 40 studies reached it within 21 months; a quarter within 15 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2016
First posted
Apr 25, 2016
StartActual
Mar 22, 2016
Primary completionActual
Jul 5, 2017
CompletionActual
May 16, 2018
Results first posted
Sep 9, 2019
Last update
Sep 9, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 9, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02750592
Responsible party
Sponsor
First posted
Apr 25, 2016
Start date
Mar 22, 2016
Primary completion
Jul 5, 2017
Completion
May 16, 2018
Results posted
Sep 9, 2019
Last update
Sep 9, 2019

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion